TIDAL 02
Alternative Names: TIDAL-02Latest Information Update: 06 Sep 2023
At a glance
- Originator Turnstone Biologics
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 06 Sep 2023 Preclinical trials in Solid tumours in Canada (Parenteral) (Turnstone Biologics pipeline; September 2023)
- 06 Sep 2023 Turnstone Biologics plans to file an IND application for Solid tumours (Turnstone Biologics pipeline; September 2023)